3 Results for "

insulin-resistant HepG2 cells

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "insulin-resistant HepG2 cells" in MCE Product Catalog:

Cat. No.: HY-114196
CAS No.: 2082752-83-6
Purity:  ≥98.0%
Synonyms: ZGN-1061
Target:  

MetAP

Research Areas:  

Metabolic Disease Cancer

Aclimostat (ZGN-1061) is a methionine aminopeptidase 2 (MetAP2) inhibitor. Aclimostat exhibits anti-obesity, anti-diabetic and ovarian cancer-related activities, and does not readily distribute to the central nervous system. Aclimostat acts on the active site of MetAP2 via irreversible covalent binding, and blocks enzyme activity through interactions with His231 and His339. Aclimostat regulates gene expression, reduces fat mass, plasma glucose, insulin levels, LDL-C, hs-CRP and leptin levels, while increasing adiponectin levels. Aclimostat can be used in research related to type 2 diabetes, overweight, obesity and ovarian cancer .
loading...
    loading...
Cat. No.: HY-187713
Target:  

Glycosidase Lipase

Research Areas:  

Metabolic Disease

α-Glucosidase-IN-122 is an inhibitor of α-glucosidase (α-Glucosidase). α-Glucosidase-IN-122 regulates glucose and lipid metabolism through multiple pathways, including inhibition of α-glucosidase and lipase, and exertion of antioxidant activity, and enhances glucose consumption in insulin-resistant HepG2 cells. α-Glucosidase-IN-122 can be used in the research of type 2 diabetes .
loading...
    loading...
Cat. No.: HY-187714
Research Areas:  

Metabolic Disease

α-Glucosidase-IN-123, a hybrid derivative of baicalein and cinnamic acid, acts as an inhibitor of α-glucosidase. α-Glucosidase-IN-123 enhances glucose uptake in insulin-resistant hepatocytes without significant cytotoxicity. α-Glucosidase-IN-123 exhibits lipase inhibitory activity and DPPH free radical scavenging activity, and it can be used in the research of type 2 diabetes .
loading...
    loading...